Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 427

1.

Percutaneous Atrial Septal Defect Closure Using the Occlutech Figulla Device in Adults: More than 800 Patient-Years of Follow-Up.

Snijder RJR, Renes LE, Bosshardt D, Suttorp MJ, Ten Berg JM, Post MC.

J Interv Cardiol. 2020 Feb 14;2020:7136802. doi: 10.1155/2020/7136802. eCollection 2020.

2.

Reloading When Switching From Ticagrelor or Prasugrel to Clopidogrel Within 7 Days After STEMI.

Claassens DMF, Tavenier AH, Hermanides RS, Vos GJA, Hinrichs DL, Bergmeijer TO, van 't Hof AWJ, Deneer VHM, Ten Berg JM.

JACC Cardiovasc Interv. 2020 Mar 9;13(5):663-665. doi: 10.1016/j.jcin.2020.01.001. No abstract available.

PMID:
32139231
3.

Personalized P2Y12 Inhibitor Treatment: Are We Ready to Go?

Ten Berg JM, Janssen PWA.

JACC Cardiovasc Interv. 2020 Mar 9;13(5):631-633. doi: 10.1016/j.jcin.2020.01.221. No abstract available.

PMID:
32139221
4.

Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score.

Angiolillo DJ, Capodanno D, Danchin N, Simon T, Bergmeijer TO, Ten Berg JM, Sibbing D, Price MJ.

JACC Cardiovasc Interv. 2020 Mar 9;13(5):606-617. doi: 10.1016/j.jcin.2020.01.226.

PMID:
32139218
5.

Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.

Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, Granger CB, Verheugt FWA, Li J, Ten Berg JM, Sarafoff N, Vranckx P, Goette A, Gibson CM, Alexander JH.

JAMA Cardiol. 2020 Feb 26. doi: 10.1001/jamacardio.2019.6175. [Epub ahead of print]

PMID:
32101251
6.

Late onset of new conduction disturbances requiring permanent pacemaker implantation following TAVI.

Kooistra NHM, van Mourik MS, Rodríguez-Olivares R, Maass AH, Nijenhuis VJ, van der Werf R, Ten Berg JM, Kraaijeveld AO, Baan J Jr, Voskuil M, Vis MM, Stella PR.

Heart. 2020 Jan 31. pii: heartjnl-2019-315967. doi: 10.1136/heartjnl-2019-315967. [Epub ahead of print]

PMID:
32005676
7.

Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.

Storey RF, Gurbel PA, Ten Berg J, Bernaud C, Dangas GD, Frenoux JM, Gorog DA, Hmissi A, Kunadian V, James SK, Tanguay JF, Tran H, Trenk D, Ufer M, Van der Harst P, Van't Hof AWJ, Angiolillo DJ.

Eur Heart J. 2019 Nov 14. pii: ehz807. doi: 10.1093/eurheartj/ehz807. [Epub ahead of print]

PMID:
31994703
8.

Genotype-guided treatment of oral P2Y12 inhibitors: where do we stand?

Claassens DM, Ten Berg JM.

Pharmacogenomics. 2020 Jan;21(2):83-86. doi: 10.2217/pgs-2019-0162. No abstract available.

9.

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation.

Steg PG, Ducrocq G, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP.

J Am Coll Cardiol. 2020 Jan 21;75(2):238-240. doi: 10.1016/j.jacc.2019.11.012. No abstract available.

PMID:
31948654
10.

Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial).

Ten Berg JM, Steg PG, Bhatt DL, Hohnloser SH, de Veer A, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Cannon CP; RE-DUAL PCI Steering Committee and Investigators.

Am J Cardiol. 2020 Mar 1;125(5):735-743. doi: 10.1016/j.amjcard.2019.11.029. Epub 2019 Dec 9.

11.

A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial.

Willemsen LM, Janssen PWA, Hackeng CM, Kelder JC, Tijssen JGP, van Straten AHM, Soliman-Hamad MA, Deneer VHM, Daeter EJ, Sonker U, Klein P, Ten Berg JM.

Am Heart J. 2020 Feb;220:237-245. doi: 10.1016/j.ahj.2019.12.001. Epub 2019 Dec 13.

PMID:
31884246
12.

Incidence of infective valve endocarditis as after antibiotic prophylaxis guidelines changed-there is a change.

van den Brink FS, Zivelonghi C, Ten Berg JM.

Ann Cardiothorac Surg. 2019 Nov;8(6):683-684. doi: 10.21037/acs.2019.06.05. No abstract available.

13.

Correction to: Guidelines for the management of myocardial infarction/injury with non-obstructive coronary arteries (MINOCA): a position paper from the Dutch ACS working group.

Pustjens TFS, Appelman Y, Damman P, Ten Berg JM, Jukema JW, de Winter RJ, Agema WRP, van der Wielen MLJ, Arslan F, Rasoul S, van 't Hof AWJ.

Neth Heart J. 2020 Jan;28(1):59. doi: 10.1007/s12471-019-01358-0.

14.

Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial.

Zilberszac R, Chandiramani R, Hengstenberg C, Sartori S, Cao D, Chandrasekhar J, Schafer U, Tchetche D, Violini R, Jeger R, Van Belle E, Boekstegers P, Hambrecht R, Tron C, Dumenteil N, Linke A, Ten Berg JM, Deliargyris EN, Anthopoulos P, Mehran R, Dangas G.

Catheter Cardiovasc Interv. 2019 Dec 5. doi: 10.1002/ccd.28642. [Epub ahead of print]

PMID:
31808295
15.

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.

Maeng M, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP; RE-DUAL PCI Steering Committee and Investigators.

JACC Cardiovasc Interv. 2019 Dec 9;12(23):2346-2355. doi: 10.1016/j.jcin.2019.07.059.

16.

Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.

Ten Berg JM, de Veer A, Oldgren J, Steg PG, Zateyshchikov DA, Jansky P, Seung KB, Hohnloser SH, Lip GYH, Nordaby M, Kleine E, Bhatt DL, Cannon CP; RE-DUAL PCI Steering Committee and Investigators.

JACC Cardiovasc Interv. 2019 Dec 9;12(23):2331-2341. doi: 10.1016/j.jcin.2019.08.039.

PMID:
31806214
17.

Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a dedicated NOAC clinic.

de Veer AJWM, Bennaghmouch N, Wijffels MCEF, Ten Berg JM.

Neth Heart J. 2019 Dec;27(12):605-612. doi: 10.1007/s12471-019-01330-y.

18.

Guidelines for the management of myocardial infarction/injury with non-obstructive coronary arteries (MINOCA): a position paper from the Dutch ACS working group.

Pustjens TFS, Appelman Y, Damman P, Ten Berg JM, Jukema JW, de Winter RJ, Agema WRP, van der Wielen MLJ, Arslan F, Rasoul S, van 't Hof AWJ.

Neth Heart J. 2020 Mar;28(3):116-130. doi: 10.1007/s12471-019-01344-6. Review. Erratum in: Neth Heart J. 2020 Jan;28(1):59.

19.

Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial.

Tavenier AH, Hermanides RS, Fabris E, Lapostolle F, Silvain J, Ten Berg JM, Lassen JF, Bolognese L, Cantor WJ, Cequier Á, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Ecollan P, Collet JP, Willems FF, Diallo A, Vicaut E, Hamm CW, Montalescot G, van 't Hof AWJ; ATLANTIC investigators.

Thromb Haemost. 2020 Jan;120(1):65-74. doi: 10.1055/s-0039-1700546. Epub 2019 Nov 21.

PMID:
31752042
21.

Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range.

Lip GYH, Bhatt DL, Hohnloser SH, Kimura T, Miede C, Nordaby M, Oldgren J, Steg PG, Ten Berg JM, Cannon CP.

J Am Coll Cardiol. 2019 Nov 12;74(19):2431-2433. doi: 10.1016/j.jacc.2019.09.009. No abstract available.

PMID:
31699285
22.

Indications for an early invasive strategy in NSTE-ACS patients.

Zwart B, Ten Berg JM, van 't Hof AW, Tonino PAL, Appelman Y, Liem AH, Arslan F, Waltenberger J, Jukema JW, de Winter RJ, Damman P.

Neth Heart J. 2020 Mar;28(3):131-135. doi: 10.1007/s12471-019-01337-5. Review.

23.

Reasons for early discontinuing or switching of antiplatelet therapy in elderly patients after acute coronary syndrome.

Gimbel ME, Vos GJA, Nguyen TA, Kelder JC, Ten Berg JM.

Coron Artery Dis. 2020 Jan;31(1):66-72. doi: 10.1097/MCA.0000000000000787.

PMID:
31609757
24.

Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients.

Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, Déry JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman R, Alexopoulos D, Kim HS, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE, Shuldiner AR.

Eur Heart J Cardiovasc Pharmacother. 2019 Sep 3. pii: pvz045. doi: 10.1093/ehjcvp/pvz045. [Epub ahead of print]

PMID:
31504375
25.

Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps.

Marx C, Novotny J, Salbeck D, Zellner KR, Nicolai L, Pekayvaz K, Kilani B, Stockhausen S, Bürgener N, Kupka D, Stocker TJ, Weckbach LT, Pircher J, Moser M, Joner M, Desmet W, Adriaenssens T, Neumann FJ, Gerschlick AH, Ten Berg JM, Lorenz M, Stark K.

Blood. 2019 Nov 21;134(21):1859-1872. doi: 10.1182/blood.2019000518.

26.

A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI.

Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van 't Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Postma MJ, de Boer A, Boersma C, Deneer VHM, Ten Berg JM.

N Engl J Med. 2019 Oct 24;381(17):1621-1631. doi: 10.1056/NEJMoa1907096. Epub 2019 Sep 3.

PMID:
31479209
27.

Alcohol septal ablation in patients with severe septal hypertrophy.

Veselka J, Jensen M, Liebregts M, Cooper RM, Januska J, Kashtanov M, Dabrowski M, Hansen PR, Seggewiss H, Hansvenclova E, Bundgaard H, Ten Berg J, Hilton Stables R, Faber L.

Heart. 2020 Mar;106(6):462-466. doi: 10.1136/heartjnl-2019-315422. Epub 2019 Aug 30.

PMID:
31471463
28.

Early Outcomes After Percutaneous Closure of Access Site in Transfemoral Transcatheter Valve Implantation Using the Novel Vascular Closure Device Collagen Plug-Based MANTA.

Gheorghe L, Brouwer J, Mathijssen H, Nijenhuis VJ, Rensing BJ, Swaans MJ, Chan Pin Yin DR, Heijmen RH, De Kroon T, Sonker U, Van der Heyden JA, Ten Berg JM.

Am J Cardiol. 2019 Oct 15;124(8):1265-1271. doi: 10.1016/j.amjcard.2019.07.030. Epub 2019 Jul 29.

PMID:
31443900
29.

Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.

Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Kiss RG, Ongen Z, Navarro Estrada JL, Oude Ophuis T, Lip GYH, Nordaby M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP; RE-DUAL PCI Steering Committee and Investigators.

JACC Cardiovasc Interv. 2019 Aug 26;12(16):1553-1561. doi: 10.1016/j.jcin.2019.05.050.

PMID:
31439336
30.

Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy-Current Evidence and Practice.

Geisler T, Jorbenadze R, Popov AF, Mueller KL, Rath D, Droppa M, Schreieck J, Seizer P, Storey RF, Kristensen SD, Rubboli A, Gorog D, Aradi D, Sibbing D, Huber K, Gawaz M, Ten Berg J.

Thromb Haemost. 2019 Oct;19(10):1590-1605. doi: 10.1055/s-0039-1694751. Epub 2019 Aug 17. Review.

PMID:
31421642
31.

Atrial fibrillation and coronary stenting: is the AUGUSTUS trial the end of triple therapy?

Zwart B, Ten Berg JM.

Future Cardiol. 2019 Sep;15(5):319-321. doi: 10.2217/fca-2019-0027. Epub 2019 Aug 6. No abstract available.

32.

First Use of Futuristic Image Fusion Technology During Transcatheter Aortic Valve Replacement.

Brouwer J, Ten Berg JM, Rensing BJWM, Swaans MJ.

JACC Cardiovasc Interv. 2019 Nov 11;12(21):2223-2224. doi: 10.1016/j.jcin.2019.06.047. Epub 2019 Jul 31. No abstract available.

PMID:
31377270
33.

Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5).

Verheugt FWA, Ten Berg JM, Storey RF, Cuisset T, Granger CB.

J Am Coll Cardiol. 2019 Aug 6;74(5):699-711. doi: 10.1016/j.jacc.2019.02.080. Epub 2019 Jul 2. Review.

PMID:
31277840
34.

Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review.

Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, Vranckx P, Lopes RD, Montalescot G, Cannon CP, Ten Berg J, Gersh BJ, Bhatt DL, Angiolillo DJ.

J Am Coll Cardiol. 2019 Jul 9;74(1):83-99. doi: 10.1016/j.jacc.2019.05.016. Review.

PMID:
31272556
35.

Measuring high on-treatment platelet reactivity in clinical practice; should we use a panel of platelet function tests?

Zwart B, Godschalk TC, Zheng K, Denteneer J, Kelder JC, Ten Berg JM.

Blood Coagul Fibrinolysis. 2019 Sep;30(6):263-269. doi: 10.1097/MBC.0000000000000831.

PMID:
31259779
36.

Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment.

Bergmeijer TO, van Oevelen M, Janssen PWA, Godschalk TC, Lichtveld RA, Kelder JC, Voskuil M, Mosterd A, Montalescot G, Ten Berg JM.

TH Open. 2018 Oct 11;2(4):e357-e368. doi: 10.1055/s-0038-1673389. eCollection 2018 Oct.

37.

Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.

Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, Granger CB, Verheugt FWA, Li J, Ten Berg JM, Sarafoff N, Gibson CM, Alexander JH.

JAMA Cardiol. 2019 Jun 19. doi: 10.1001/jamacardio.2019.1880. [Epub ahead of print]

PMID:
31215979
38.

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.

Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong YH, Mehran R, Moliterno DJ, Neumann FJ, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF, Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo DJ.

JACC Cardiovasc Interv. 2019 Aug 26;12(16):1521-1537. doi: 10.1016/j.jcin.2019.03.034. Epub 2019 Jun 12. Review.

PMID:
31202949
39.

Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCI-the POPular Risk Score study.

Janssen PWA, Bergmeijer TO, Vos GA, Kelder JC, Qaderdan K, Godschalk TC, Breet NJ, Deneer VHM, Hackeng CM, Ten Berg JM.

Eur J Clin Pharmacol. 2019 Sep;75(9):1201-1210. doi: 10.1007/s00228-019-02696-z. Epub 2019 Jun 14.

PMID:
31197411
40.

Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis.

Veselka J, Faber L, Liebregts M, Cooper R, Januska J, Kashtanov M, Dabrowski M, Hansen PR, Seggewiss H, Hansvenclova E, Bundgaard H, Ten Berg J, Stables RH, Jensen MK.

Eur Heart J. 2019 Jun 1;40(21):1681-1687. doi: 10.1093/eurheartj/ehz110.

PMID:
31152553
41.

Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial.

Power D, Schäfer U, Guedeney P, Claessen BE, Sartori S, Sorrentino S, Lefèvre T, Kupatt C, Tchetche D, Dumonteil N, Webb JG, Colombo A, Windecker S, Ten Berg JM, Hildick-Smith D, Boekstegers P, Linke A, Tron C, Van Belle E, Asgar AW, Jeger R, Sardella G, Hink U, Husser O, Grube E, Lechthaler I, Wijngaard P, Anthopoulos P, Deliargyris EN, Bernstein D, Hengstenberg C, Mehran R, Dangas GD.

Catheter Cardiovasc Interv. 2019 Jun 1;93(7):1374-1381. doi: 10.1002/ccd.28295. Epub 2019 May 22.

PMID:
31116908
42.

Veno arterial-extra corporal membrane oxygenation for the treatment of cardiac failure in patients with infective endocarditis.

van den Brink FS, van Tooren R, Sonker U, Klein P, Waanders F, Zivelonghi C, Eefting FD, Scholten E, Ten Berg JM.

Perfusion. 2019 Oct;34(7):613-617. doi: 10.1177/0267659119842807. Epub 2019 Apr 26.

PMID:
31027458
43.

Sex differences in characteristics and outcome in acute coronary syndrome patients in the Netherlands.

Ten Haaf ME, Bax M, Ten Berg JM, Brouwer J, Van't Hof AW, van der Schaaf RJ, Stella PR, Tjon Joe Gin RM, Tonino PA, de Vries AG, Zijlstra F, Boersma E, Appelman Y.

Neth Heart J. 2019 May;27(5):263-271. doi: 10.1007/s12471-019-1271-0.

44.

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.

Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP.

Am Heart J. 2019 Jun;212:13-22. doi: 10.1016/j.ahj.2019.02.006. Epub 2019 Mar 1.

PMID:
30928824
45.

A "minimalistic hybrid algorithm" in coronary chronic total occlusion revascularization: Procedural and clinical outcomes.

Zivelonghi C, van Kuijk JP, Poletti E, Suttorp MJ, Eefting FD, Rensing BJ, Ten Berg JM, Colombo A, Azzalini L, Agostoni P.

Catheter Cardiovasc Interv. 2020 Jan;95(1):97-104. doi: 10.1002/ccd.28213. Epub 2019 Mar 14.

PMID:
30919577
46.

Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events.

Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dubé MP, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Bogaty P, de Borst GJ, Brenner H, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Johnson JA, de Jong PA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus JA, Stewart AFR, Szczeklik W, Szpakowicz A, Ten Berg JM, Thanassoulis G, Thiery J, van der Graaf Y, Visseren FLJ, Waltenberger J; CARDIoGRAMPlusC4D Consortium, Van der Harst P, Tardif JC, Sattar N, Lang CC, Pare G, Brophy JM, Anderson JL, März W, Wallentin L, Cameron VA, Horne BD, Samani NJ, Hingorani AD, Asselbergs FW.

Circ Genom Precis Med. 2019 Apr;12(4):e002471. doi: 10.1161/CIRCGEN.119.002471. Epub 2019 Mar 21.

PMID:
30897348
47.

Subsequent Event Risk in Individuals With Established Coronary Heart Disease.

Patel RS, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behloui H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engstrøm T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots ML, Brenner H, Brugts JJ, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, Danchin N, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Grobbee DE, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Jabbari R, Johnson JA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Niemcunowicz-Janica A, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Siegbahn A, Simon T, Sinisalo J, Smith JG, Spertus JA, Stender S, Stewart AFR, Szczeklik W, Szpakowicz A, Tardif JC, Ten Berg JM, Tfelt-Hansen J, Thanassoulis G, Thiery J, Torp-Pedersen C, van der Graaf Y, Visseren FLJ, Waltenberger J, Weeke PE, Van der Harst P, Lang CC, Sattar N, Cameron VA, Anderson JL, Brophy JM, Pare G, Horne BD, März W, Wallentin L, Samani NJ, Hingorani AD, Asselbergs FW.

Circ Genom Precis Med. 2019 Apr;12(4):e002470. doi: 10.1161/CIRCGEN.119.002470. Epub 2019 Mar 21.

PMID:
30896328
48.

Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation.

Nijenhuis VJ, Brouwer J, Søndergaard L, Collet JP, Grove EL, Ten Berg JM.

Heart. 2019 May;105(10):742-748. doi: 10.1136/heartjnl-2018-314313. Epub 2019 Mar 13. Review.

PMID:
30867148
49.

Will intravenous paracetamol crush fentanyl in patients undergoing PCI for STEMI?

Ten Berg JM, Claassens DMF.

Neth Heart J. 2019 Apr;27(4):169-170. doi: 10.1007/s12471-019-1262-1. No abstract available.

50.

Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial).

Nijenhuis VJ, Ten Berg JM, Hengstenberg C, Lefèvre T, Windecker S, Hildick-Smith D, Kupatt C, Van Belle E, Tron C, Hink HU, Colombo A, Claessen B, Sartori S, Chandrasekhar J, Mehran R, Anthopoulos P, Deliargyris EN, Dangas G.

Am J Cardiol. 2019 May 1;123(9):1494-1500. doi: 10.1016/j.amjcard.2019.01.049. Epub 2019 Feb 10.

PMID:
30826050

Supplemental Content

Loading ...
Support Center